Skip to Content

'
Ralph B. Arlinghaus, Ph.D.

Present Title & Affiliation

Primary Appointment

Hubert L. Stringer Chair in Cancer Research, Department of Translational Molecular Pathology, Division of Pathology/Lab Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Dual/Joint/Adjunct Appointment

Member of the Graduate Faculty, The University of Texas Graduate School of Biomedical Sciences, Houston, TX

Office Address

The University of Texas MD Anderson Cancer Center
2130 W. Holcombe Blvd
Unit Number: 2951
Houston, TX 77030
Room Number: Life Science Plaza Bldg - LSP9.4001

Education & Training

Degree-Granting Education

1961 University of Cincinnati, College of Medicine, Cincinnati, OH, PHD, Biochemistry
1959 University of Cincinnati, Graduate School of Arts, Cincinnati, OH, MS, Pharmaceutical Chemistry
1957 University of Cincinnati, College of Pharmacy, Cincinnati, OH, BS, Pharmacy

Experience/Service

Academic Appointments

Professor & Chair, Department of Translational Molecular Pathology, Division of Pathology/Lab Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 7/1998-8/2012
Professor, Chair, Deputy Division Head, Department of Translational Molecular Pathology, Division of Pathology, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 7/1986-8/1998
Visiting Investigator (Member), Scripps Clinic & Research Foundation, LaJolla, CA, 1/1983-1/1986
Professor, Chair Ad Interim, Deputy Division Head, Department of Tumor Virology, U.T. System Cancer Center, M. D. Anderson Hospital & Tumor Institute, Houston, TX, 1/1976-1/1983

Institutional Committee Activities

Member, Institutional Research Executive Committee, 2/2012-present
Member, Biochemistry & Molecular Biology Search Committee, 1/1988-1989
Member, Executive Committee of the Science Faculty, 1/1983-9/2011
Member, Symposium Committee for Basic Science, MDA, 1/1976
Member, Symposium Committee on Fundamental Cancer Res, 1/1974-1/1975

Honors and Awards

1994-present Hubert L. Stringer Chair in Cancer Research, The University of Texas MD Anderson Cancer Center

Selected Publications

Peer-Reviewed Original Research Articles

1. Singh MM, Irwin ME, Gao Y, Ban K, Shi P, Arlinghaus RB, Amin HM, Chandra J. Inhibition of the NADPH oxidase regulates heme oxygenase 1 expression in chronic myeloid leukemia. Cancer 118(13):3433-45, 7/1/2012. e-Pub 12/2/2011. PMCID: PMC3297684.
2. Samanta A, Perazzona B, Chakraborty S, Sun X, Modi H, Bhatia R, Priebe W, Arlinghaus R. Janus kinase 2 regulates Bcr-Abl signaling in chronic myeloid leukemia. Leukemia 25(3):463-472, 3/2011. e-Pub 12/24/2010. PMCID: PMC3072513.
3. Jatiani SS, Cosenza SC, Reddy MV, Ha JH, Baker SJ, Samanta AK, Olnes MJ, Pfannes L, Sloand EM, Arlinghaus RB, Reddy EP. A non-ATP-Competitive Dual Inhibitor of JAK2V617F and BCR-ABLT3151 Kinases: Elucidation of a novel therapeutic spectrum based on substrate competitive inhibition. Genes Cancer 1(4):331-45, 4/2010. PMCID: PMC2921666.
4. Samanta AK, Chakraborty SN, Wang Y, Schlette E, Reddy EP, Arlinghaus RB. Destabilization of Bcr-Abl/Jak2 network by a Jak2/Abl kinase inhibitor ON044580 overcomes drug resistance in blast crisis chronic myelogenous leukemia (CML). Genes Cancer 1(4):346-59, 4/2010. PMCID: PMC2927857.
5. Leng X, Ding T, Lin H, Wang Y, Hu L, Hu J, Feig B, Zhang W, Pusztai L, Symmans WF, Wu Y, Arlinghaus RB. Inhibition of Lipocalin 2 Impairs Breast Tumorigenesis and Metastasis. Cancer Res 69(22):8579-84, 11/15/2009. e-Pub 11/3/2009. PMID: 19887608.
6. Hu L, Hittelman W, Lu T, Ji P, Arlinghaus R, Shmulevich I, Hamilton SR, Zhang W. NGAL decreases E-cadherin-mediated cell-cell adhesion and increases cell motility and invasion through Rac1 in colon carcinoma cells. Lab Invest 89(5):531-48, 5/2009. e-Pub 3/23/2009. PMID: 19308044.
7. Samanta AK, Chakraborty SN, Wang Y, Kantarjian H, Sun X, Hood J, Perrotti D, Arlinghaus RB. Jak2 inhibition deactivates Lyn kinase through the SET-PP2A-SHP1 pathway causing apoptosis in drug-resistant cells from chronic myelogenous leukemia patients. Oncogene 28(14):1669-81, 4/9/2009. e-Pub 2/23/2009. PMCID: PMC2841483.
8. Muehlberg FL, Song YH, Krohn A, Pinilla SP, Droll LH, Leng X, Seidensticker M, Ricke J, Altman AM, Devarajan E, Liu W, Arlinghaus RB, Alt EU. Tissue resident stem cells promote breast cancer growth and metastasis. Carcinogenesis 30(4):588-97, 4/2009. e-Pub 1/30/2009. PMID: 19181699.
9. Leng X, Lin H, Ding T, Wang Y, Wu Y, Klumpp S, Sun T, Zhou Y, Monaco P, Belmont J, Aderem A, Akira S, Strong R, Arlinghaus R. Lipocalin 2 is required for BCR-ABL-induced tumorigenesis. Oncogene 27(47):6110-9, 10/16/2008. e-Pub 7/28/2008. PMCID: PMC2756829.
10. Zhang H, Trachootham D, Lu W, Carew J, Giles FJ, Keating MJ, Arlinghaus RB, Huang P. Effective killing of Gleevec-resistant CML cells with T315I mutation by a natural compound PEITC through redox-mediated mechanism. Leukemia 22(6):1191-9, 6/2008. e-Pub 4/3/2008. PMCID: PMC2585768.
11. Tao WJ, Lin H, Sun T, Samanta AK, Arlinghaus R. BCR-ABL oncogenic transformation of NIH 3T3 fibroblasts requires the IL-3 receptor. Oncogene 27(22):3194-200, 5/15/2008. e-Pub 12/10/2007. PMCID: PMC2756828.
12. Perazzona B, Lin H, Sun T, Wang Y, Arlinghaus R. Kinase domain mutants of Bcr enhance Bcr-Abl oncogenic effects. Oncogene 27(15):2208-14, 4/3/2008. e-Pub 10/15/2007. PMCID: PMC2585769.
13. Zhang H, Trachootham D, Lu W, Carew J, Giles FJ, Keating MJ, Arlinghaus RB, Huang P. Effective Killing of Gleevec-Resistant CML-Cells with T3151 Mutation by a Natural Compound PEITC through Redox-Mediated Mechanism. Leukemia 22(6):1191-9, 4/2008. PMCID: PMC18385754.
14. Arlinghaus R, Leng X. Requirement of lipocalin 2 for chronic myeloid leukemia. Leuk Lymphoma 49(4):600-3, 4/2008. PMID: 18398717.
15. Ban K, Gao Y, Amin HM, Howard A, Miller C, Lin Q, Leng X, Munsell M, Bar-Eli M, Arlinghaus RB, Chandra J. BCR-ABL1 Mediates Up-Regulation of Fyn in Chronic Myelogenous Leukemia. Blood 111(5):2904-8, 3/1/2008. e-Pub 1/7/2008. PMCID: PMC2254539.
16. Lin J, Arlinghaus R. Activated c-Abl tyrosine kinase in malignant solid tumors. Oncogene 27(32):4385-91, 2008. PMCID: PMC18391983.
17. Tari AM, Gutiérrez-Puente Y, Monaco G, Stephens C, Sun T, Rosenblum M, Belmont J, Arlinghaus R, Lopez-Berestein G. Liposome-incorporated Grb2 antisense oligodeoxynucleotide increases the survival of mice bearing bcr-abl-positive leukemia xenografts. Int J Oncol 31(5):1243-50, 11/2007. PMID: 17912453.
18. Lin J, Sun T, Ji L, Deng W, Roth J, Minna J, Arlinghaus R. Oncogenic activation of c-Abl in non-small cell lung cancer cells lacking FUS1 expression: inhibition of c-Abl by the tumor suppressor gene product Fus1. Oncogene 26(49):6989-96, 10/25/2007. e-Pub 5/7/2007. PMID: 17486070.
19. Trachootham D, Zhou Y, Zhang H, Demizu Y, Chen Z, Pelicano H, Chiao PJ, Achanta G, Arlinghaus RB, Liu J, Huang P. Selective killing of oncogenically transformed cells through a ROS-mediated mechanism by beta-phenylethyl isothiocyanate. Cancer Cell 10(3):241-52, 9/2006. PMID: 16959615.
20. Samanta AK, Lin H, Sun T, Kantarjian H, Arlinghaus RB. Janus kinase 2: a critical target in chronic myelogenous leukemia. Cancer Res 66(13):6468-72, 7/1/2006. PMID: 16818614.
21. Ling X, Wang Y, Dietrich MF, Andreeff M, Arlinghaus RB. Vaccination with Leukemia cells expressing cell surface-associated GM-CSF blocks leukemia induction in immunocompetent mice. Oncogene 25(32):4483-90, 7/27/2006. e-Pub 3/20/2006. PMID: 16547503.
22. Verstovsek S, Golemovic M, Kantarjian H, Manshouri T, Estrov Z, Manley P, Sun T, Arlinghaus RB, Alland L, Dugan M, Cortes J, Giles F, Beran M. AMN107, a novel aminopyrimidine inhibitor of p190 Bcr-Abl activation and of in vitro proliferation of Philadelphia-positive acute lymphoblastic leukemia cells. Cancer 104(6):1230-6, 9/15/2005. PMID: 16078266.
23. Golemovic M, Verstovsek S, Giles F, Cortes J, Manshouri T, Manley PW, Mestan J, Dugan M, Alland L, Griffin JD, Arlinghaus RB, Sun T, Kantarjian H, Beran M. AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has in vitro activity against imatinib-resistant chronic myeloid leukemia. Clin Cancer Res 11(13):4941-7, 7/1/2005. PMID: 16000593.
24. Lin H, Monaco G, Sun T, Ling X, Stephens C, Xie S, Belmont J, Arlinghaus R. Bcr-Abl-mediated suppression of normal hematopoiesis in leukemia. Oncogene 24(20):3246-56, 5/5/2005. PMID: 15735695.
25. Ling X, Arlinghaus RB. Knockdown of STAT3 expression by RNA interference inhibits the induction of breast tumors in immunocompetent mice. Cancer Res 65(7):2532-6, 4/1/2005. PMID: 15805244.
26. Donato NJ, Wu JY, Stapley J, Lin H, Arlinghaus R, Aggarwal BB, Shishodia S, Albitar M, Hayes K, Kantarjian H, Talpaz M. Imatinib mesylate resistance through BCR-ABL independence in chronic myelogenous leukemia. Cancer Res 64(2):672-7, 1/2004. PMCID: PMC14744784.
27. Katayama H, Sasai K, Kawai H, Yuan ZM, Bondaruk J, Suzuki F, Fujii S, Arlinghaus RB, Czerniak BA, Sen S. Phosphorylation by aurora kinase A induces Mdm2-mediated destabilization and inhibition of p53. Nat Genet 36(1):55-62, 1/2004. e-Pub 12/14/2003. PMID: 14702041.
28. Wang L, Duke L, Zhang PS, Arlinghaus RB, Symmans WF, Sahin A, Mendez R, Dai JL. Alternative splicing disrupts a nuclear localization signal in spleen tyrosine kinase that is required for invasion suppression in breast cancer. Cancer Res 63(15):4724-30, 8/1/2003. PMID: 12907655.
29. Mahon GM, Wang Y, Korus M, Kostenko E, Cheng L, Sun T, Arlinghaus RB, Whitehead IP. The c-Myc Oncoprotein Interacts with Bcr. Curr Biol 13(5):437-41, 3/4/2003. PMID: 12620195.
30. Ling X, Ma G, Sun T, Liu J, Arlinghaus RB. Bcr and Abl interaction: oncogenic activation of c-Abl by sequestering Bcr. Cancer Res 63(2):298-303, 1/15/2003. PMID: 12543778.
31. Donato NJ, Wu JY, Stapley J, Gallick G, Lin H, Arlinghaus R, Talpaz M. BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. Blood 101(2):690-8, 1/15/2003. PMID: 12509383.
32. Kantarjian HM, Cortes JE, O'Brien S, Giles F, Garcia-Manero G, Faderl S, Thomas D, Jeha S, Rios MB, Letvak L, Bochinski K, Arlinghaus R, Talpaz M. Imatinib mesylate therapy in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia: high incidence of early complete and major cytogenetic responses. Blood 101(1):97-100, 1/1/2003. e-Pub 8/29/2002. PMID: 12393600.
33. Kantarjian HM, Talpaz M, Cortes J, O'Brien S, Faderl S, Thomas D, Giles F, Rios MB, Shan J, Arlinghaus R. Quantitative polymerase chain reaction monitoring of BCR-ABL during therapy with imatinib mesylate (STI571; gleevec) in chronic-phase chronic myelogenous leukemia. Clin Cancer Res 9(1):160-6, 1/2003. PMID: 12538464.
34. Arlinghaus RB. Bcr: a negative regulator of the Bcr-Abl oncoprotein in leukemia. Oncogene 21(56):8560-7, 12/9/2002. PMID: 12476302.
35. Guo JQ, Lin H, Kantarjian H, Talpaz M, Champlin R, Andreeff M, Glassman A, Arlinghaus RB. Comparison of competitive-nested PCR and real-time PCR in detecting BCR-ABL fusion transcripts in chronic myeloid leukemia patients. Leukemia 16(12):2447-53, 12/2002. PMID: 12454751.
36. Xie S, Lin H, Sun T, Arlinghaus RB. Jak2 is involved in c-Myc induction by Bcr-Abl. Oncogene 21(47):7137-46, 10/17/2002. PMID: 12370803.
37. Kantarjian HM, O'Brien S, Cortes JE, Giralt SA, Rios MB, Shan J, Giles FJ, Thomas DA, Faderl S, De Lima M, Garcia-Manero G, Champlin R, Arlinghaus R, Talpaz M. Imatinib mesylate therapy for relapse after allogeneic stem cell transplantation for chronic myelogenous leukemia. Blood 100(5):1590-5, 9/1/2002. PMID: 12176876.
38. Atallah E, Talpaz M, O'brien S, Rios MB, Guo JQ, Arlinghaus R, Fernandes-Reese S, Kantarjian H. Chronic myelogenous leukemia in T cell lymphoid blastic phase achieving durable complete cytogenetic and molecular remission with imatinib mesylate (STI571; Gleevec) therapy. Cancer 94(11):2996-9, 6/1/2002. PMID: 12115389.
39. Verstovsek S, Lin H, Kantarjian H, Saglio G, De Micheli D, Pane F, Garcia-Manero G, Intrieri M, Rotoli B, Salvatore F, Guo JQ, Talpaz M, Specchia G, Pizzolo G, Liberati AM, Cortes J, Quackenbush RC, Arlinghaus RB. Neutrophilic-chronic myeloid leukemia: low levels of p230 BCR/ABL mRNA and undetectable BCR/ABL protein may predict an indolent course. Cancer 94(9):2416-25, 5/1/2002. PMID: 12015767.
40. Tan M, Jing T, Lan KH, Neal CL, Li P, Lee S, Fang D, Nagata Y, Liu J, Arlinghaus R, Hung MC, Yu D. Phosphorylation on tyrosine-15 of p34(Cdc2) by ErbB2 inhibits p34(Cdc2) activation and is involved in resistance to taxol-induced apoptosis. Mol Cell 9(5):993-1004, 5/2002. PMID: 12049736.
41. Lin H, Guo JQ, Andreeff M, Arlinghaus RB. Detection of dual TEL-ABL transcripts and a Tel-Abl protein containing phosphotyrosine in a chronic myeloid leukemia patient. Leukemia 16(2):294-7, 2/2002. PMID: 11840298.
42. Hawk N, Sun T, Xie S, Wang Y, Wu Y, Liu J, Arlinghaus RB. Inhibition of the Bcr-Abl oncoprotein by Bcr requires phosphoserine 354. Cancer Res 62(2):386-90, 1/15/2002. PMID: 11809685.
43. Kardinal C, Konkol B, Lin H, Eulitz M, Schmidt EK, Estrov Z, Talpaz M, Arlinghaus RB, Feller SM. Chronic myelogenous leukemia blast cell proliferation is inhibited by peptides that disrupt Grb2-SoS complexes. Blood 98(6):1773-81, 9/15/2001. PMID: 11535511.
44. Che W, Abe J, Yoshizumi M, Huang Q, Glassman M, Ohta S, Melaragno MG, Poppa V, Yan C, Lerner-Marmarosh N, Zhang C, Wu Y, Arlinghaus R, Berk BC. p160 Bcr mediates platelet-derived growth factor activation of extracellular signal-regulated kinase in vascular smooth muscle cells. Circulation 104(12):1399-406, 9/18/2001. PMID: 11560856.
45. Sun T, Campbell M, Gordon W, Arlinghaus RB. Preparation and application of antibodies to phosphoamino acid sequences. Biopolymers 60(1):61-75, 6/2001. PMCID: PMC11376433.
46. Lin F, Monaco G, Sun T, Liu J, Lin H, Stephens C, Belmont J, Arlinghaus RB. BCR gene expression blocks Bcr-Abl induced pathogenicity in a mouse model. Oncogene 20(15):1873-81, 4/5/2001. PMID: 11313935.
47. Wang Y, Liu J, Wu Y, Luo W, Lin SH, Lin H, Hawk N, Sun T, Guo JQ, Estrov Z, Talpaz M, Champlin R, Arlinghaus RB. Expression of a truncated first exon BCR sequence in chronic myelogenous leukemia cells blocks cell growth and induces cell death. Cancer Res 61(1):138-44, 1/1/2001. PMID: 11196151.
48. Kardinal C, Konkol B, Schulz A, Posern G, Lin H, Adermann K, Eulitz M, Estrov Z, Talpaz M, Arlinghaus RB, Feller SM. Cell-penetrating SH3 domain blocker peptides inhibit proliferation of primary blast cells from CML patients. FASEB J 14(11):1529-38, 8/2000. PMID: 10928987.
49. Wu Y, Liu J, Arlinghaus RB. Requirement of two specific tyrosine residues for the catalytic activity of Bcr serine/threonine kinase. Oncogene 16(1):141-6, 1/8/1998. PMID: 9467953.
50. Liu J, Wu Y, Arlinghaus RB. Sequences within the first exon of BCR inhibit the activated tyrosine kinases of c-Abl and the Bcr-Abl oncoprotein. Cancer Res 56(22):5120-4, 11/15/1996. PMID: 8912843.
51. Wilson-Rawls J, Xie S, Liu J, Laneuville P, Arlinghaus RB. P210 Bcr-Abl interacts with the interleukin 3 receptor beta(c) subunit and constitutively induces its tyrosine phosphorylation. Cancer Res 56(15):3426-30, 8/1/1996. PMID: 8758906.

Invited Articles

1. Leng X, Wu Y, Arlinghaus RB. Relationships of Lipocalin 2 with Breast Tumorigenesis and Metastasis. J Cell Physiol 226(2):309-14, 2/2011. e-Pub 9/2010. PMID: 20857428.
2. Lin J, Arlinghaus R. Activated c-Abl tyrosine kinase in malignant solid tumors. Oncogene 27(32):4385-91, 7/24/2008. e-Pub 4/7/2008. PMID: 18391983.
3. Guo JQ, Lian J, Xian YM, Arlinghaus RB. Enhanced detection of BCR-ABL protein in blood cells of Philadelphia chromsome positive leukemia patients using ECL. Amersham Corporation, Arlington Heights, IL. 2006.

Abstracts

1. Neviani P, Harb JG, Oaks JJ, Walker C, Santhanam R, Paisie C, Eiring A, Zhang B, Perazzona B, Ma Y, Mao C, Marcucci G, Holyoake TL, Volinia S, Cortes JE, Caligiuri MA, Huettner C, Bittman R, Chen CS, Arlinghaus RB, Hokland P, Roy DC, Bhatia R, Perrotti D. BCR-ABL1 Kinase Activity but Not its Expression is Dispensable for Ph+ Quiescent Stem Cell Survival which Depends on the PP2A-Controlled Jak2 Activation and is Sensitive to FTY720 Treatment. ASH 52nd Annual Meeting (#515), 12/2010.
2. DeGeer D, Gallipoli P, Chen M, Sloma I, Jorgensen H, Forrest D, Lambie K, Nakamoto H, Saw KM, Chan M, Newmarch K, Zhou L, Turhan AG, Arlinghaus RB, Eaves AC, Eaves CJ, Holyoake TL, Jiang X. Combined Targeting of BCR-ABL and JAK2 with ABL and JAK2 Inhibitors is Effective Against CML Patients' Leukemic Stem/Progenitor Cells. ASH 52nd Annual Meeting (#3404), 12/2010.
3. Samanta AK, Perazzona B, Chakraborty SN, Sun X, Modi H, Bhatia R, Arlinghaus RB. Jak2 Regulates Bcr-Abl in CD34+ Cells from Imatinib Mesylate-Resistant CML Patients. ASH 52nd Annual Meeting (#1220), 12/2010.
4. Chen M, Zhou L, Chan M, Lai D, Turhan AG, Arlinghaus RB, Jiang X. The WD40-Repeats of Ahi-1 Oncogene Critical for Protein Interaction Between Ahi-1 and BCR-ABL Modulates Imatinib-Induced Apoptosis in BCR-ABL Transduced Cells. ASH 52nd Annual Meeting (#4181), 12/2010.

Book Chapters

1. Arlinghaus RB. Involvement of the abl proto-oncogene in human leukemias. In: Genes and Cancer. John Wiley & Sons, Ltd. London, England, 65-71. Chapter 6, 2006.
2. Arlinghaus RB, Sun T. Signal transduction pathways in Bcr-Abl transformed cells. In: Cancer Treat Res. 119. Kluwer Academic Publishers: Norwell, MA, 119:239-70, 2004. ISBN: 15164881.

Letters to the Editor

1. Chakraborty S, Lin YH, Leng X, Miranda RN, Medeiros LJ, Shpall E, Arlinghaus RB. Activation of Jak2 in patients with blast crisis chronic myelogenous leukemia: Inhibition of Jak2 inactivates Lyn kinase. Blood Cancer J 3:e142, 2013. e-Pub 9/6/2013. PMCID: PMC3789205.

Grant & Contract Support

Title: Identification of New Targets and Novel Treatment Strategies for Chronic Myeloid Leukemia
Funding Source: NIH/NCI
Role: Project Leader
Principal Investigator: Richard Champlin
Duration: 7/1/2010 - 6/30/2015

Last updated: 12/31/2013